Cardio Support

$50.00 $43.95

Click to enlarge

Supports Health Heart Function
A Result of 20 Years of Clinical Study and Research

Cardio Support is the result of 20 years’ study by a top Chinese university research group. Large amounts of data have shown the safety and efficacy of Cardio Support through preclinical, animal testing to pharmacologic and toxicologic studies, to phase 1 and phase 2 clinical trials. Results demonstrate that this traditional Chinese formula is effective in addressing heart problems due blockage in the arteries that lead to chest pain-- especially upon activity shortness of breath, tiredness, dizziness, among other related physical discomfort.

Ingredients:

Astragalus (huang qi)
Rehmannia Glutinosa (di huang)
Ophiopogon (mai dong)
Schisandra (wu wei zi)
Chinese Peony (chi shao)
Cassia (gui zhi)

The formulation of Cardio Support is based on ancient Chinese medicine principles. Then by using modern manufacturing techniques, its safety, purity, and stability are ensured. The primary herbs are:

Chief herb: Huang Qi (astragalus) is aimed at tonifying the qi and strengthening the heart to support Heart yang.
Supporting herbs: Shu Di Huang (rehmannia glutinosa) is aimed at nourishing Heart yin and heart muscle, and benefiting the heart and promoting blood flow. Gui Zhi (Cassia) is aimed at guiding all herbs to the heart, so that yang is supported and qi is benefited, and heart yin is nourished.

PHARMACODYNAMIC STUDIES
Results of laboratory animal studies assessing the pharmacodynamics of Cardio Support are summarized as follows.

The effects of Cardio Support on neonate rat myocardial cell damage induced by isopropylarterenol in vitro were studied. Results indicate that Cardio Support appears to slow the pulse rate of myocardial cells, enhance pulse strength, regulate pulse rhythm, and improve the fluidity of myocardial cell membrane. Cardio Support also appears to have a protective effect on cell mitochondria. Conclusion: Cardio Support shows protective effect on myocardial cell damage induced by isopropylarterenol in vitro.

The pathology of the protective function of Cardio Support on laboratory rat myocardial necrosis induced by isopropylarterenol was observed. Results show the area, quality, and extent of myocardial necrosis in Cardio Support -treated groups were significantly lower than those in control animals. Conclusion: Cardio Support appears to be effective in alleviating myocardial damage resulting from anoxia and ischemia of cardiocytes.

Rat model of myocardial obstructive ischemic injury was established by ligation of the coronary artery. The protective effect of Cardio Support on myocardial damage was then observed. Conclusion: Cardio Support is capable of improving the ECG of rats with such myocardial injury.

Results from experiments on the protective effects of Cardio Support on laboratory rat myocardial necrosis are as follows: Cardio Support can decrease the activities of phosphocreatine kinase (CPK), lactate dehydrogenase (LDH), glutamic-oxalacetic transaminase (GOT), and hydroxybutyrate dehydrogenase (HBDH). Conclusion: Cardio Support appears to improve myocardial nutrition metabolism.

Other experiments found that Cardio Support appears to alleviate myocardial necrosis and reduce free fatty acid (FFA) concentration and TBA value of lipid peroxide in rat plasma. Conclusion: Cardio Support may enhance the body’s ability to scavenge free radicals.

A study on the acute hemodynamic effects of Cardio Support on patients with congestive heart failure (CHF) due to ischemic or dilated cardiomyopathy was performed between two groups (Cardio Support -treated group and a water-only group as control). The disease stage of both groups was nearly the same. Results indicate that mean pulmonary arterial pressure (MPAP) and pulmonary wedge pressure (PWP) were markedly reduced in the Cardio Support -treated group, and their cardiac index (CI, using thermodilution method) was significantly elevated. These effects were not observed in the control group. Conclusion: In CHF, Cardio Support appears to reduce symptoms by improving the pumping function the heart and not by changing blood volume.

PHARMACOLOGY STUDIES
An acute toxicity test showed that the median lethal dose (LD50) of Cardio Support was more than 220 g/kg. According to the acute toxicity of chemicals classification standards, Cardio Support is a nontoxic medicine.

A long-term toxicity test showed that rat weight, liver and kidney functions, hemogram and main organs were without obvious damage three months after Cardio Support was given to the animals by gastric feeding.

CLINICAL STUDIES
Phase I clinical trial: 31 hospitalized cases with myocardial ischemia injury induced by heart disease were studied. After receiving Cardio Support, clinical efficacy rate was 87.09%, and efficacy rate as shown by ECG was 41.93%. This is compared to the control group on propranolol, composed of 15 hospitalized patients, whose clinical efficacy result were 66.67% and ECG efficacy rate was 40.00%.

Phase II clinical trial: Among 304 cases of myocardial damage, clinical results found 100 cases were markedly improved, 189 cases improved, and 15 cases with showed no improvement. Overall effective rate was 95.06%. ECG results found 86 were markedly improved, 104 improved, and 114 showed no improvement. Overall effective rate was 62.50%. Therapeutic effect in the Cardio Support -treated group of 100 patients was superior to that of the comparison group of 100 patients who received propranolol. Only 9 of the 304 patients treated with Cardio Support experienced side effects, which included temporary dry mouth, nausea, loose stool or constipation. No other adverse effects were observed. Cardio Support has no adverse effects on liver and kidney function, or on routine blood and urine tests.

The clinical studies indicate that Cardio Support can eliminate clinical symptoms, regulate blood pressure, and improve myocardial microcirculation without any obvious effect on heart rate. Cardio Support can also enhance blood erythrocyte superoxide dismutase (SOD) activity and reduce plasma blood lipid peroxide (LPO) concentration. These activities were far better than those in the propranolol group. The results show that Cardio Support can improve myocardial function and cell recovery following injury, and that hemodynamically, Cardio Support may have a positive inotropic function, since it reduces pulmonary artery pressure and pulmonary capillary wedge pressure.

Phase I and phase II clinical studies show that Cardio Support is a safe, effective traditional Chinese medicine treatment for myocardial damage.

FUNCTIONS and INDICATIONS of CARDIO SUPPORT
Function: Benefiting qi and yang; nourishing heart yin; alleviating myocardial anoxia and ischemia; improving myocardial function and cell recovery following injury.

Indications: Chest blockage and pain (biomedical conditions of coronary artery disease, angina, hypertensive heart disease); palpitation (due to cardiomyopathy, myocarditis). Symptoms include chest pain and fullness that comes and goes, palpitation, shortness of breath, dizziness, fatigue, crimson tongue, weak or irregular pulse. ECG results include changes in S-T or T wave.

TYPICAL CASES
Cheng, male, 62 years old: Experienced repeated episodes of chest pain over 5 years, and was admitted to abnormalities of the S-T segment and T wave. Tongue was reddish and pulse was thin and weak. Traditional Chinese diagnosis: chest obstruction. Biomedical diagnosis: angina as caused by coronary artery disease. Cardio Support was administered at 20g, 3 times a day. By the second week of treatment, all symptoms were improved, by four weeks, symptoms were markedly improved, and by the end of 6 weeks (1 course of treatment), all symptoms were relieved. Repeat ECG revealed restoration of the S-T segment and elevation of the T wave. Routine urinalysis and blood work were normal. Patient continued on Cardio Support with no relapses of angina.

Liu, male, 56 years old: Experienced chest pain 4 to 5 times daily over 4 months. Each bout lasted 5 to 19 minutes. The pain was aggravated by activity, and relieved with nitroglycerin and rest. He was hypertensive with a blood pressure of 213/120 mmHg. Physical examination found the lungs clear. Chest palpation revealed normal heart size; heart rate was 84/minute. Blood, urine, liver, and kidneys were all normal. X-ray and ultrasound results were all normal. ECG reading was abnormal. Exercise stress test results were positive for myocardial ischemia. He was diagnosed as having angina. After taking 1 course (6 weeks) of Cardio Support (20g, three times daily), symptoms were relieved and ECG reading was normal. Follow-up for 6 months found patient’s condition was stable without further episodes of angina.the hospital 1 day following the most recent episode. Upon admission, symptoms included: chest pain, palpitation, shortness of breath, dizziness. Patient complained of 3 attacks a day, with pain radiating to the shoulder and back. Upon examination both lungs were clear, chest palpation revealed the heart to be of normal size, heart rate was 80/minute, rhythm was regular, heart valve sounds were normal, and liver and spleen were normal. Lower extremities did not show edema. Blood pressure was 135/82 mmHg. Routine urinalysis and blood work were normal; liver and kidney functions were normal. X-ray and ultrasound imaging of the heart revealed no abnormalities.

**No medical claim is either expressed or implied.

This product was added to our catalog on Tuesday 05 June, 2007.

Customers who bought this product also purchased

Dieter's Choice for Carb Control	Vital Yew	Curamin
Cardio B